These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 25271760)
1. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity. Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds. Wu F; Jiang H; Zheng B; Kogiso M; Yao Y; Zhou C; Li XN; Song Y J Med Chem; 2015 Sep; 58(17):6899-6908. PubMed ID: 26280302 [TBL] [Abstract][Full Text] [Related]
3. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration. Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer. Wu F; Cheng G; Yao Y; Kogiso M; Jiang H; Li XN; Song Y Med Chem; 2018; 14(7):715-724. PubMed ID: 29792149 [TBL] [Abstract][Full Text] [Related]
5. Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction. Zhou X; Zheng M; Zhao N; Hu Y; Yang K; Huo J; Liu G; Huang J; Chen L; Zhou Y; Li H Bioorg Chem; 2022 Feb; 119():105569. PubMed ID: 34954572 [TBL] [Abstract][Full Text] [Related]
6. Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study. Xu T; Yang J; Li D; Challa M; Zou C; Deng P; Zhang SL; Xu B Eur J Med Chem; 2024 Sep; 275():116610. PubMed ID: 38896992 [TBL] [Abstract][Full Text] [Related]
7. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Pusch S; Krausert S; Fischer V; Balss J; Ott M; Schrimpf D; Capper D; Sahm F; Eisel J; Beck AC; Jugold M; Eichwald V; Kaulfuss S; Panknin O; Rehwinkel H; Zimmermann K; Hillig RC; Guenther J; Toschi L; Neuhaus R; Haegebart A; Hess-Stumpp H; Bauser M; Wick W; Unterberg A; Herold-Mende C; Platten M; von Deimling A Acta Neuropathol; 2017 Apr; 133(4):629-644. PubMed ID: 28124097 [TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation. Wen F; Gui G; Wang X; Qin A; Ma T; Chen H; Li C; Zha X J Med Chem; 2024 Jun; 67(11):8667-8692. PubMed ID: 38651495 [TBL] [Abstract][Full Text] [Related]
9. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer. Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596 [TBL] [Abstract][Full Text] [Related]
10. Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. Zou F; Pusch S; Hua J; Ma T; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X Bioorg Med Chem Lett; 2018 Feb; 28(3):388-393. PubMed ID: 29290542 [TBL] [Abstract][Full Text] [Related]
11. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1). Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781 [TBL] [Abstract][Full Text] [Related]
12. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1. Ma T; Zou F; Pusch S; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X Bioorg Med Chem; 2017 Dec; 25(24):6379-6387. PubMed ID: 29089260 [TBL] [Abstract][Full Text] [Related]
14. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Rohle D; Popovici-Muller J; Palaskas N; Turcan S; Grommes C; Campos C; Tsoi J; Clark O; Oldrini B; Komisopoulou E; Kunii K; Pedraza A; Schalm S; Silverman L; Miller A; Wang F; Yang H; Chen Y; Kernytsky A; Rosenblum MK; Liu W; Biller SA; Su SM; Brennan CW; Chan TA; Graeber TG; Yen KE; Mellinghoff IK Science; 2013 May; 340(6132):626-30. PubMed ID: 23558169 [TBL] [Abstract][Full Text] [Related]
15. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804 [TBL] [Abstract][Full Text] [Related]
16. 3-(7-Azaindolyl)-4-indolylmaleimides as a novel class of mutant isocitrate dehydrogenase-1 inhibitors: Design, synthesis, and biological evaluation. Hu Y; Gao A; Liao H; Zhang M; Xu G; Gao L; Xu L; Zhou Y; Gao J; Ye Q; Li J Arch Pharm (Weinheim); 2018 Oct; 351(10):e1800039. PubMed ID: 30113716 [TBL] [Abstract][Full Text] [Related]
17. A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit. Kopinja J; Sevilla RS; Levitan D; Dai D; Vanko A; Spooner E; Ware C; Forget R; Hu K; Kral A; Spacciapoli P; Kennan R; Jayaraman L; Pucci V; Perera S; Zhang W; Fischer C; Lam MH Sci Rep; 2017 Oct; 7(1):13853. PubMed ID: 29062039 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors. Liu X; Hu Y; Gao A; Xu M; Gao L; Xu L; Zhou Y; Gao J; Ye Q; Li J Bioorg Med Chem; 2019 Feb; 27(4):589-603. PubMed ID: 30600148 [TBL] [Abstract][Full Text] [Related]
19. Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase. Zheng B; Yao Y; Liu Z; Deng L; Anglin JL; Jiang H; Prasad BV; Song Y ACS Med Chem Lett; 2013 Jun; 4(6):542-546. PubMed ID: 23795241 [TBL] [Abstract][Full Text] [Related]
20. A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model. Machida Y; Nakagawa M; Matsunaga H; Yamaguchi M; Ogawara Y; Shima Y; Yamagata K; Katsumoto T; Hattori A; Itoh M; Seki T; Nishiya Y; Nakamura K; Suzuki K; Imaoka T; Baba D; Suzuki M; Sampetrean O; Saya H; Ichimura K; Kitabayashi I Mol Cancer Ther; 2020 Feb; 19(2):375-383. PubMed ID: 31727689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]